Kusurinomadoguchi (5592) Fundamentals 2026 — P/E 8.7x, Revenue Analysis | SniperIQ
Kusurinomadoguchi (5592) is a JP-listed Healthcare company in Medical - Healthcare Information Services with a market capitalization of ¥26.2B, trading at ¥2288.00 on the JPX. This SniperIQ fundamentals page covers Kusurinomadoguchi's valuation (P/E 8.7x, P/B 2.3x), profitability (net margin 23.9%), revenue (¥12.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kusurinomadoguchi's market cap?
Kusurinomadoguchi (5592) has a market capitalization of approximately ¥26.2B, trading at ¥2288.00 on the JPX. Market cap moves with the live share price.
What is Kusurinomadoguchi's P/E ratio?
Kusurinomadoguchi's trailing twelve-month P/E ratio is 8.7x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kusurinomadoguchi?
Kusurinomadoguchi runs a net profit margin of 23.9%, a gross margin of 56.5%, and an operating margin of 21.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kusurinomadoguchi generate?
Kusurinomadoguchi reported revenue of ¥12.3B for fiscal year 2025, with net income of ¥3.0B and earnings per share (EPS) of 263.24. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kusurinomadoguchi pay a dividend?
Kusurinomadoguchi offers a trailing dividend yield of about 1.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Kusurinomadoguchi financially healthy?
Kusurinomadoguchi carries a debt-to-equity ratio of 0.25x and a current ratio of 1.94x, with a market beta of 0.83. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kusurinomadoguchi a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kusurinomadoguchi (5592) the key facts are: market cap ¥26.2B, P/E 8.7x, revenue ¥12.3B, 52-week range 2065-4685. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kusurinomadoguchi's full fundamentals live
Get Kusurinomadoguchi's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.